TTakeda will contribute the research and development portfolio and personnel in the renal, metabolic, and cardiovascular therapeutic areas to support the launch of the new company, located within Takeda’s Shonan Research Institute. This venture is a large-scale public-private project between Innovation Network Corporation of Japan (INCJ), Takeda and MediPal Holdings Co., a holding which controls the prescription pharmaceutical wholesale business, the cosmetics, daily necessities and OTC pharmaceutical wholesale business, and the animal health products and food processing raw materials wholesale business of a wide range of companies. The three parties will jointly invest 10 billion yen. The Innovation Network Corporation of Japan (INCJ), capitalized at 300 billion yen, was founded 2009 by the Japanese government, injecting 286 billion yen, and 26 private corporations, and provides financial, technological and management support for next-generation businesses.

Takeda news release, March 14, 2017